tiprankstipranks
Trending News
More News >
StemRIM Inc. (JP:4599)
:4599
Japanese Market

StemRIM Inc. (4599) AI Stock Analysis

Compare
0 Followers

Top Page

JP

StemRIM Inc.

(4599)

Rating:47Neutral
Price Target:
StemRIM Inc.'s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and ongoing net losses. While the company maintains a solid equity base, the lack of profitability and negative cash flows present significant risks. Technical analysis shows some short-term momentum but longer-term weakness. Valuation metrics are unattractive due to negative earnings. Overall, the company's current financial challenges overshadow potential strengths, leading to a cautious outlook.

StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)

StemRIM Inc. Business Overview & Revenue Model

Company DescriptionStemRIM Inc. (4599) is a biotechnology company focused on the research and development of regenerative medicine technologies. The company operates within the healthcare sector, specifically targeting the development of therapies that promote tissue regeneration and repair. StemRIM's core products and services include regenerative medicine research, therapeutic development, and potential clinical applications aimed at treating various medical conditions.
How the Company Makes MoneyStemRIM Inc. generates revenue primarily through the development and commercialization of regenerative medicine therapies. This includes income from licensing agreements, research collaborations, and potential partnerships with pharmaceutical companies and research institutions. The company may also receive funding from grants and government research initiatives aimed at advancing regenerative medicine. Additionally, as its therapies advance through clinical trials, StemRIM could earn revenue from milestone payments and eventual product sales upon regulatory approval.

StemRIM Inc. Financial Statement Overview

Summary
StemRIM Inc. faces significant financial challenges, evidenced by its declining revenue, persistent net losses, and negative cash flows. Despite a solid equity base and low leverage, the company's current financial trajectory is concerning. The biotech sector's inherent risks, coupled with the company's operational inefficiencies, underscore the need for strategic shifts to stabilize and grow revenue streams sustainably.
Income Statement
35
Negative
StemRIM Inc.'s income statement reflects significant volatility in revenue and profitability. There is a marked revenue collapse from 2.35 billion JPY in 2023 to zero in 2024, accompanied by substantial net losses over the years. The gross and net profit margins are negative, indicating high operational costs relative to revenue. The EBIT and EBITDA margins are also negative, further reflecting operational inefficiencies. Overall, the company's profitability is weak, and the recent revenue drop raises concerns about its growth potential.
Balance Sheet
65
Positive
The balance sheet of StemRIM Inc. shows a strong equity base with a high equity ratio due to minimal debt, resulting in a low debt-to-equity ratio. This financial structure suggests low leverage risk. However, the consistent net losses have impacted the company's return on equity, which remains negative. The high cash reserves provide liquidity, but the declining asset base could be a concern if not addressed through revenue growth.
Cash Flow
40
Negative
The cash flow statement indicates a challenging cash flow situation with negative operating and free cash flows in 2024, highlighting cash burn issues. The free cash flow growth rate is negative, and the ratios of operating and free cash flow to net income are weak due to ongoing losses. This situation suggests potential difficulties in sustaining operations without external financing if the revenue situation does not improve.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
0.000.002.35B22.98M1.40B2.10B
Gross Profit
-33.35M-44.35M2.30B22.98M1.40B2.10B
EBIT
-2.16B-2.08B142.39M-1.98B-593.73M415.71M
EBITDA
-2.10B-2.03B218.05M-1.90B-532.23M369.06M
Net Income Common Stockholders
-2.12B-2.02B168.35M-1.95B-582.45M347.76M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.02B8.41B10.22B8.88B10.17B10.68B
Total Assets
8.67B9.08B10.71B9.60B10.91B11.28B
Total Debt
0.000.00531.00K3.67M6.73M9.71M
Net Debt
-8.02B-8.41B-10.22B-8.88B-10.17B-10.67B
Total Liabilities
273.69M185.88M336.02M192.43M212.64M431.36M
Stockholders Equity
8.40B8.89B10.37B9.40B10.70B10.85B
Cash FlowFree Cash Flow
0.00-1.88B1.13B-1.40B-609.23M422.44M
Operating Cash Flow
0.00-1.88B1.14B-1.40B-519.65M575.41M
Investing Cash Flow
0.00-4.78M-344.00K-330.00K-92.72M-153.71M
Financing Cash Flow
0.0078.97M202.60M112.86M109.32M7.76B

StemRIM Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price347.00
Price Trends
50DMA
310.70
Positive
100DMA
319.96
Positive
200DMA
342.37
Negative
Market Momentum
MACD
7.48
Negative
RSI
54.91
Neutral
STOCH
58.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Positive. The current price of 347 is above the 20-day moving average (MA) of 320.30, above the 50-day MA of 310.70, and above the 200-day MA of 342.37, indicating a neutral trend. The MACD of 7.48 indicates Negative momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 58.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4599.

StemRIM Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$1.30T25.476.04%2.33%8.90%-37.00%
71
Outperform
$2.49T48.683.22%5.36%19.25%294.48%
70
Neutral
¥1.14T24.635.34%3.97%6.42%10.82%
67
Neutral
$6.44T22.1517.60%1.74%17.77%48.97%
65
Neutral
$6.89T63.561.50%4.52%7.45%-25.77%
54
Neutral
$5.24B3.26-44.35%6.48%16.78%-0.10%
47
Neutral
¥20.94B
-100.00%-1079.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4599
StemRIM Inc.
331.00
-43.00
-11.50%
JP:4503
Astellas Pharma
1,355.50
-135.72
-9.10%
JP:4151
Kyowa Kirin Co
2,479.00
-158.86
-6.02%
JP:4523
Eisai Co
3,986.00
-2,292.48
-36.51%
JP:4502
Takeda Pharmaceutical Co
4,298.00
383.40
9.79%
JP:4568
Daiichi Sankyo Company
3,380.00
-1,985.21
-37.00%

StemRIM Inc. Corporate Events

StemRIM Inc. Announces Shareholder Meeting and Capital Reduction
Apr 9, 2025

StemRIM Inc. has announced the setting of a record date for an Extraordinary General Meeting of Shareholders and a capital stock reduction. The capital reduction aims to enhance financial flexibility and reduce tax burdens without affecting the company’s net assets or shareholders’ equity. This strategic financial maneuver is expected to streamline StemRIM’s capital policies, subject to shareholder approval, and reflects the company’s commitment to maintaining operational efficiency.

StemRIM Secures Chinese Patent for Redasemtide, Boosting Global Expansion
Apr 3, 2025

StemRIM Inc. has secured a patent in China for its peptide drug Redasemtide, aimed at treating traumatic articular cartilage deficiency syndrome, osteoarthritis, and osteochondritis dissecans. This patent is expected to enhance the development potential of Redasemtide in China, a rapidly growing pharmaceutical market, and support the global expansion of StemRIM’s ‘Regeneration-Inducing Medicine™’. While the immediate financial impact is minimal, the patent positions StemRIM strategically in the global biotech industry.

StemRIM’s Redasemtide Trial Advances with Promising Interim Results
Apr 2, 2025

StemRIM Inc. announced the interim analysis results of its global Phase 2b clinical trial for Redasemtide, a treatment for acute ischemic stroke, conducted in collaboration with Shionogi & Co., Ltd. The trial, which spans 18 countries, aims to evaluate Redasemtide’s efficacy in patients not eligible for endovascular recanalization therapy. The interim analysis recommended continuing the trial for the 1.5 mg/kg dose group while discontinuing the 0.75 mg/kg group, aligning with initial expectations and potentially reducing the required number of subjects. This development is significant for the clinical advancement of Redasemtide, although it currently has no impact on StemRIM’s financial results for the fiscal year ending July 31, 2025.

StemRIM Inc. Reports Financial Loss Amid Ongoing R&D Investments
Mar 12, 2025

StemRIM Inc. reported a net loss for the six months ending January 31, 2025, with no operating revenue recorded. The company’s financial position showed a decrease in total assets and net assets compared to the previous period. Despite the financial challenges, StemRIM remains committed to its R&D efforts, with significant cash outflows expected for research and development through 2028. The company has not provided a financial forecast for the fiscal year ending July 31, 2025, due to the unpredictable nature of milestone revenues from development partnerships.

StemRIM Amends Phase 2b Trial Protocol for Stroke Treatment
Mar 2, 2025

StemRIM Inc. announced a protocol amendment for its global Phase 2b clinical trial of Redasemtide, a treatment for acute ischemic stroke, which is being conducted in collaboration with Shionogi & Co., Ltd. The amendment includes adding a new cohort of patients who have undergone endovascular recanalization therapy and relaxing eligibility criteria, allowing broader patient participation without significantly extending the trial period. This adjustment is crucial as the market for ischemic stroke treatments is expected to reach $10.56 billion by 2027, and the changes aim to adapt to the evolving treatment landscape.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.